MAYNE PHARMA INC
SpecialtyMAYNE PHARMA INC is a specialty pharmaceutical company focused on Dermatology, Immunology. Key products include TOLSURA.
FDA Novel Drug Designations
(2018-2021)See 2 novel approvals →
MAYNE PHARMA INC at a Glance
- Strong track record with 88% execution quality across 8 trials
- Fast trial execution (10 months median completion)
MAYNE PHARMA INC's Key Drugs
MAYNE PHARMA INC's core commercial portfolio centers on TOLSURA, RHOFADE, IMVEXXY, spanning Dermatology and Immunology — its most strategically important drugs approved in the last 15 years.
Blastomycosis
Rosacea
Dyspareunia
Pregnancy prevention
Acne Vulgaris
MAYNE PHARMA INC's Recent FDA Approvals
New NDA/BLA approvals for MAYNE PHARMA INC over the last two years — novel drugs only, excluding generics and label supplements.
MAYNE PHARMA INC's Therapeutic Areas
MAYNE PHARMA INC's approved drugs and pipeline span 2 therapeutic areas, led by Dermatology and Immunology, across 0 biologic and 10 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MAYNE PHARMA INC's Top Competitors
MAYNE PHARMA INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MAYNE PHARMA INC Pipeline Snapshot
MAYNE PHARMA INC has 3 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 3 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TOLSURA leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/2 completed
- • Speed: 10 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (3)
Company Info
- First Approval
- 1985-07-22
- Latest
- 2026-02-12
- Applications
- 17
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges